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OBJECTIVES: There has been a growing concern about the economic burden of
work incapacity due to mental health problems; meanwhile studies examining the
employer’s perspective are still scarce. This study aims to propose a rationale to
estimate the burden of mental health problems in Brazilian corporations.
METHODS:Data from an observational study investigating absenteeism due to sick
leaves in a Brazilian bank were used to build a costing estimation model (total
number of employees, average number of sick days per employee, and proportion
of sick days due to mental ill health). These data were combined with average wage
and turnover rate national statistics and published data on presenteeism due to
mental health problems. RESULTS: Based on n7499 workers, 3.36 annual sick
days per employee, a proportion of sick days attributable to mental health disor-
ders of 15.58%, and a mean daily wage of 51.33BRL, the costing model projected
annual costs due to absenteeism of 201,534BRL. If presenteeism is included in the
costing estimation, using a previously published presenteeism/absenteeism ratio
of 4.0 (for depressed workers), costs due to presenteeism would represent
806,138BRL per year. There is a lack of Brazilian observational studies assessing
turnover rates and associated costs. National rates according to economic sector
were employed to estimate the impact of turnover of mental ill workers (Service
Industry4.15% in 2010) and a turnover cost of 3 times the average monthly cost
per employee were used as a proxy. Turnover costs would incur in additional
115,500BRL per year. The annual economic burden of mental health disorders un-
der the employers perspective was estimated in 1,123,173BRL. CONCLUSIONS: The
cost of mental ill health to employers, particularly the cost of productivity losses
due to lower performance of employees at work (presenteeism), can represent a
significant burden for companies and society.
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OBJECTIVES:Mental illnesses in Pakistan are at rise. Decade long terrorism, suicide
bombing, recent floods, political uncertainty and transition to market economy are
some of the key factors that are contributing to increasing mental illnesses in the
country. This study emphasizes the importance of economic consequences of
mental illness in Pakistan and provides estimates of cost on mental illness in the
country. METHODS: Aga Khan University Hospital patient records of psychiatry
clinics inpatient (N727) and outpatient (N1458) data for the year 2005-06 were
classified into ten ICD-10 classification. For each category of mental illness the
direct cost included consultation fee, diagnostics, bed charges, laboratory charges
medication and procedure. The indirect costs on travel and productivity losses are
being estimated drawing a stratified random sample for both inpatient and day
care dataset. RESULTS: Mental illnesses categories 2(Schizophrenia (N227) and
3(mood/depressive disorder (N415) accounted for 82% of burden of mental ill-
nesses in inpatient care. While in day care 2(Schizophrenia 3(mood/depressive
disorder and 4(Panic/OCD) accounted for 75 % of the burden of mental illnesses in
Pakistan. Mean cost for all categories in inpatient care is Pak Rs. 21701 per treat-
ment episode. Illnesses category 8 (anorexia) was the most costly (MeanRs.71687)
and category 1(dementia and other organic disorders were relatively less expensive
to treat (MeanPak Rs.1183). CONCLUSIONS: Initial findings suggest the economic
burden of mental illnesses is alarmingly high and its treatment is unaffordable by
many families in the country. This might result in denied or delayed care. Using
country level available data on burden of mental illness the economic impact of
mental illnesses in Pakistan will be estimated. We will also explain socio-economic
determinates of mental illnesses.
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OBJECTIVES: There is little data describing current practice in the clinical manage-
ment of patients with psychosis and co-occurring substance use and the associated
costs. In the UK, standard psychiatric care is based on the care programme ap-
proach and includes community and hospital-based treatment. Inpatient psychi-
atric treatment is the key cost driver of psychiatric care. This study aimed to de-
scribe practice-based patient-level costs of inpatient psychiatric treatment for NHS
patients with psychosis and co-occurring substance use. METHODS: Resource use
data of inpatient psychiatric treatment were collected from the medical records of
327 patients recruited in the MIDAS trial, a randomised controlled trial of an ex-
perimental intervention programme (integrated motivational interviewing and
cognitive-behaviour therapy, MiCBT) plus standard care or standard care alone.
Using the hospital perspective, data were collected from trial entry until end of
2-year trial follow-up (between 2004 to 2009). Unit costs were assigned, based on
NHS Reference Costs 2008/09 and PSSRU 2009. Data were analysed using descrip-
tive statistics and variations around the costs were obtained. RESULTS: Of the 327
patients, 95 patients (29%) experienced at least one episode of hospitalisation, with
a mean of 85 inpatient days (95% CI: 65 – 105, median 42, range 2 - 568) per hospi-
talised patient. Total cost for these 95 patients was £2.43million (UK £2008/09) over
8,108 inpatient days. Mean cost per hospitalised patient was £25,547 (95% CI:
£18,453 – £32,640, median £12,180, range £580 – £273,208). Cost components com-
prised: acute psychiatric admission (total 6,428 days, £1.86million), psychiatric re-
habilitation admission (total 621 days, £165,186), psychiatric long-stay admission
(total 434 days, £91,574), psychiatric ICU admission (total 57 days, £32,832) and
psychiatric forensic medium secure unit admission (568 days, £273,208).
CONCLUSIONS: This study provided practice-based data describing patient-level
costs associated with standard NHS care of inpatient psychiatric treatment for
patients with psychosis and co-occurring substance use.
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OBJECTIVES: Pharmacological strategies for schizophrenia have received increas-
ing attention due to the development of new and costly drug therapies. To estimate
the direct healthcare and non-healthcare cost of schizophrenia and to simulate
cost reductions potentially obtained with a new pharmacogenomics treatment, in
a cohort of patients newly diagnosed with schizophrenia, over the first 5 years
following their diagnosis. METHODS: A microsimulation Monte-Carlo Markov
model was used. Six discrete disorder states defined the Markov model: 1): first
episode (FE); 2) low dependency state (LDS); 3) high dependency state (HDS); 4)
Stable state (Stable); 5) Well state (Well); and 6) Death state (Death). Costs and
individual probabilities of transition were estimated from the Régie de l’assurance
maladie du Québec and Med-Echo databases. RESULTS: A total of 14,320 individu-
als were identified in the study cohort as newly diagnosed patients with schizo-
phrenia. Over the first 5 years following diagnosis the mean cost per person was
estimated at $36,701 (95%CI: 36,264 to 37,138). The direct health care cost accounted
for 56.2% of the total cost, welfare assistance for 34.6% and long term care facilities
for 9.2%. On the direct health care cost, hospitalisation cost accounted for 64.6%,
medical cost for 11.4% and drug-related cost for 24%. In the case where a new
pharmacogenomic treatment with 20% increase of effectiveness will be available,
the direct healthcare and non-health care costs can be reduced up to 14.2%.
CONCLUSIONS: This model is the first Canadian model incorporating transition
probabilities adjusted for individual risk-factor profiles and costs using real-life
data. Our results indicate that a new pharmacogenomics treatment could possibly
reduce hospitalization and long-term care facility costs while potentially enabling
patients to return to active employment that would in turn contribute to the re-
duction of the welfare assistance cost.
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OBJECTIVES: People addicted to opioids contribute a significant burden to society,
both in terms of quality of life (QoL) and economic consequences. Untreated users
are more likely to be out of work, commit crimes and require healthcare resources.
Treating patients has been demonstrated to reduce these factors. However, some
users receiving formal care continue to misuse that treatment, leading to other
significant consequences for society. This study evaluated the potential impact of
a novel formulation (buprenorphine/naloxone; suboxone), aimed at mitigating
misuse and diversion. Increasing the currently limited number of treatments avail-
able will likely increase the number of people in treatment. The objective was to
assess cost-effectiveness of two approaches to managing opioid users, buprenor-
phine/naloxone and methadone, and, further, to compare the use of any treatment
against no treatment. METHODS: A cost-effectiveness model was built, incorpo-
rating the costs and benefits associated with each treatment. Healthcare unit cost
data were taken from published data and databases, including NHS Reference
Costs 2009-2010 and PSSRU Unit Costs of Health and Social Care 2010. Crime costs
were taken from Home Office publications. Crime and hospitalisation rates, by
treatment, were taken from an observational study of 109 patients in Scotland.
Health related QoL figures, by treatment, were taken from an SF-36 questionnaire
study. RESULTS: Over 6 months, it was estimated that savings associated with
reduced crime (buprenorphine/naloxone versus methadone) were £2129, and sav-
ings from reduced health care visits were £1409. Based on a combination of mor-
tality and QoL improvements, patients on buprenorphine/naloxone were shown to
gain 0.087 QALYs compared to those receiving methadone. CONCLUSIONS: The
model showed that the cost implications of crime, hospitalisation and misuse and
diversion were key drivers of the results. Use of buprenorphine/naloxone resulted
in a saving of £3538 due to reduced crime and hospitalisations, whilst providing a
benefit to QoL.
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OBJECTIVES: The objective of this exploratory analysis was to assess the cost-
effectiveness of quetiapineXR as monotherapy compared to other key drug treat-
ments in MDD patients, who have failed on previous therapy.METHODS:A Markov
Model with one week cycles was used to assess the cost effectiveness of quetiap-
ineXR treatment over 52 weeks. Key outcomes were: response rates, costs and
Incremental Cost-Effectiveness Ratios (ICERs) for second line monotherapy. The
A291V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
